Author： Le Brun P.P.H. de Boer A.H. Mannes G.P.M. de Frature D.M.I. Brimicombe R.W. Touw D.J. Vinks A.A. Frijlink H.W. Heijerman H.G.M.
Publisher： Elsevier
ISSN： 0939-6411
Source： European Journal of Pharmaceutics and Biopharmaceutics, Vol.54, Iss.1, 2002-07, pp. : 25-32
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
By de Boer A.H. Le Brun P.P.H. van der Woude H.G. Hagedoorn P. Heijerman H.G.M. Frijlink H.W.
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 54, Iss. 1, 2002-07 ,pp. :
Access to resources
Recommend
Mannitol Dry Powder for Inhalation: In Patients with Cystic Fibrosis
By Burness Celeste B. Keating Gillian M.
Drugs, Vol. 72, Iss. 10, 2012-07 ,pp. :
Effect of Particle Formulation on Dry Powder Inhalation Efficiency
Current Pharmaceutical Design, Vol. 16, Iss. 21, 2010-07 ,pp. :
Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design, Vol. 21, Iss. 27, 2015-01 ,pp. :